Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission Company expects to commence bioavailability study in April 2025 Aspire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback